In conclusion, our results suggest that the rs187084 polymorphism may be associated with an elevated cancer risk, whereas polymorphisms of rs352140 and rs5743836 may play protective roles in the development of breast and digestive system cancers, respectively.
However, no significantly increased cancer risk was detected to be associated with rs187084</span> and rs5743836 either the overall or subgroup estimation.